实用药物与临床
實用藥物與臨床
실용약물여림상
PRACTICAL PHARMACY AND CLINICAL REMEDIES
2014年
4期
472-475
,共4页
带状疱疹%药物治疗%用药分析
帶狀皰疹%藥物治療%用藥分析
대상포진%약물치료%용약분석
Herpes zoster%Drug therapy%Analysis of drug use
目的:了解临床上带状疱疹患者的用药现状。方法抽取我院2012年带状疱疹出院患者病历400份,设计调查表,摘录其治疗信息,对其用药情况进行统计、分析。结果该病好发于成人(99.7%),尤以中老年人更为多见(89.7%)。以抗病毒(95.0%)、营养神经(100%)、止痛(100%)、局部治疗(100%)、糖皮质激素治疗(40.0%)及免疫调节(36.5%)为主要治疗方案。经治疗,患者病情均有所改善,治愈率为10.0%,显效率达55.3%。伐昔洛韦和喷昔洛韦抗病毒治疗有效率均高于阿昔洛韦治疗组(P<0.05或P<0.01);联用胸腺肽治疗组有效率高于未联用胸腺肽治疗组(P<0.01)。结论治疗带状疱疹应根据患者的具体情况进行个体化给药,方能达到治疗的最佳效果。
目的:瞭解臨床上帶狀皰疹患者的用藥現狀。方法抽取我院2012年帶狀皰疹齣院患者病歷400份,設計調查錶,摘錄其治療信息,對其用藥情況進行統計、分析。結果該病好髮于成人(99.7%),尤以中老年人更為多見(89.7%)。以抗病毒(95.0%)、營養神經(100%)、止痛(100%)、跼部治療(100%)、糖皮質激素治療(40.0%)及免疫調節(36.5%)為主要治療方案。經治療,患者病情均有所改善,治愈率為10.0%,顯效率達55.3%。伐昔洛韋和噴昔洛韋抗病毒治療有效率均高于阿昔洛韋治療組(P<0.05或P<0.01);聯用胸腺肽治療組有效率高于未聯用胸腺肽治療組(P<0.01)。結論治療帶狀皰疹應根據患者的具體情況進行箇體化給藥,方能達到治療的最佳效果。
목적:료해림상상대상포진환자적용약현상。방법추취아원2012년대상포진출원환자병력400빈,설계조사표,적록기치료신식,대기용약정황진행통계、분석。결과해병호발우성인(99.7%),우이중노년인경위다견(89.7%)。이항병독(95.0%)、영양신경(100%)、지통(100%)、국부치료(100%)、당피질격소치료(40.0%)급면역조절(36.5%)위주요치료방안。경치료,환자병정균유소개선,치유솔위10.0%,현효솔체55.3%。벌석락위화분석락위항병독치료유효솔균고우아석락위치료조(P<0.05혹P<0.01);련용흉선태치료조유효솔고우미련용흉선태치료조(P<0.01)。결론치료대상포진응근거환자적구체정황진행개체화급약,방능체도치료적최가효과。
Objective To understand the situation of drug use for herpes zoster in the clinic. Methods 400 discharge cases of herpes zoster were collected from our hospital in 2012. The investigation report was designed to ex-tract the patient′s information. The utilization of drugs was analyzed statistically. Results The disease was more likely to occur in adults (99. 7%),and the higher incidence of herpes zoster had been found in middle-aged and elderly peo-ple (89. 7%). The main therapeutic scheme included:anti-virus (95. 0%),neurotrophic treatment (100%),pain relief (100%),topical treatment (100. 0%),glucocorticoid treatment (40. 0%) and immune regulation (36. 5%). After treatment,the condition of all the patients had been improved. The curative rate and marked effective rate were 10. 0%and 55. 3%. The effective rate of valaciclovir group or penciclovir group was higher than that of aciclovir group respec-tively ( P<0. 05 or P<0. 01 ) . The effective rate of combined with thymosin group was higher than that of no com-bined with thymosin group (P<0. 01). Conclusion Individual drug scheme should be provided for the treatment of herpes zoster according to the specific situation of patients so as to achieve a better treatment outcome.